To develop novel strategies to reprogram the immunosuppressive tumor microenvironment (TME) toward an immunostimulatory transcriptional program in order to restore cytotoxicity T cell activation and sensitize tumors for cancer immunotherapy. We utilize state-of-the-art CyTOF, single-cell RNA sequencing, bioinformatics, computational modeling, tumor models and tumor organoids to investigate mechanisms of resistance and acquired resistance to immunotherapy.
Yong Lu, PhD
Associate Professor of Immunology, Academic Institute
Associate Member, Research Institute
Scientist, Research Institute
Dr. Mary and Ron Neal Cancer Center
Since 2020, Dr. Lu has been awarded, as the PI, 4 R01s from NCI, 1 ACS research scholar grant, 3 cancer foundation grants, and numerous intramural and industry grants. In addition to the CPRIT Rising Star award, Dr. Lu was the winner of New Drug Development Global Campaign in 2019 held by Daiichi Sankyo Co., Ltd.